Skip to content

What an FDA drug or biologic submission contains

Oak
A large reptile lies on a plinth with its armoured back plates raised like pages, light showing beneath each.

A sponsor files an investigational new drug application with FDA before administering an investigational drug to human subjects. The marketing application that follows is a new drug application, an abbreviated new drug application or a biologics license application. Parts 312, 314 and 601 of 21 CFR set the content of each filing, the procedure for submitting it and the way FDA reaches a decision.

The investigational new drug application

Part 312 applies to clinical investigations of products subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act. A sponsor must submit an IND before conducting such an investigation and must not begin the investigation until the IND is in effect.1 An IND goes into effect 30 days after FDA receives it, unless FDA notifies the sponsor that the investigations are subject to a clinical hold under § 312.42. It takes effect earlier if FDA notifies the sponsor in writing that the clinical investigations may begin. An investigator may not administer the drug to human subjects before that date.1

Section 312.23(a) requires the IND to be submitted in a stated order, beginning with a cover sheet on Form FDA-1571. The cover sheet contains the following.1

  • The name, address and telephone number of the sponsor, the date of the application and the name of the investigational new drug.
  • Identification of the phase or phases of the clinical investigation to be conducted.
  • A commitment not to begin clinical investigations until an IND covering them is in effect.
  • A commitment that an Institutional Review Board complying with part 56 will be responsible for initial and continuing review and approval of each study.
  • A commitment to conduct the investigation in accordance with all other applicable regulatory requirements.
  • The name and title of the person responsible for monitoring the conduct and progress of the clinical investigations.
  • The names and titles of the persons responsible under § 312.32 for review and evaluation of safety information.

The amount of information required depends on the novelty of the drug, the extent of previous study, the known or suspected risks and the developmental phase. Section 312.22(c) states that the central focus of the initial submission should be the general investigational plan and the protocols for specific human studies. FDA’s review of Phase 1 submissions focuses on the safety of the proposed investigations. Its review of Phase 2 and Phase 3 submissions also assesses scientific quality and the likelihood that the studies will yield data capable of meeting the statutory standards for marketing approval.1

Reports, amendments and meetings under an IND

An IND is a living file. A sponsor submits a protocol amendment for a study not covered by a protocol already in the IND, and that study may begin once the protocol has been submitted to FDA and approved by the responsible IRB, in either order.1 Essential information outside the scope of a protocol amendment, a safety report or an annual report goes in an information amendment under § 312.31, which should be submitted no more often than every 30 days to the extent feasible. Section 312.33 requires an annual progress report within 60 days of the anniversary date on which the IND went into effect.1

Meetings are available throughout. Section 312.47 identifies end-of-Phase 2 meetings and pre-NDA meetings held near the completion of Phase 3 as especially useful. For products intended to treat life-threatening or severely debilitating illnesses, § 312.82 provides for pre-IND meetings and end-of-phase 1 meetings to reach agreement on study design. A sponsor or investigator must not represent in a promotional context that an investigational drug is safe or effective for the purposes under investigation.1

What a new drug application contains

Section 314.50 requires NDAs and supplements to approved NDAs to be submitted in the form and with the information appropriate for the particular submission. Three copies are required: an archival copy, a review copy and a field copy. An NDA for a new chemical entity generally contains the following.

  • an application form
  • an index
  • a summary
  • five or six technical sections
  • case report tabulations of patient data
  • case report forms
  • drug samples
  • labeling, including any Medication Guide required under part 208

Other NDAs, including 505(b)(2) applications, amendments and supplements, generally contain only some of those items.2

The NDA must contain reports of all investigations of the drug product sponsored by the applicant. It must also contain all other information about the drug pertinent to an evaluation of the NDA that the applicant received or obtained from any source. FDA maintains guidance documents on the format and content of NDAs.2 Separate provisions govern pediatric assessment data under § 314.55, patent information on the required FDA declaration form under § 314.53 and waiver requests under § 314.90.

Abbreviated and 505(b)(2) applications

An ANDA under § 314.94 also requires three copies. Its archival copy includes an application form drawing on § 314.50(a), a table of contents showing volume and page numbers, and a statement of the basis for submission naming the reference listed drug with its dosage form and strength. A 505(b)(2) application is available where investigations other than bioavailability or bioequivalence studies are essential to approval of a modification of a listed drug. Under § 314.54 it need contain only the information needed to support that modification.

Where a 505(b)(2) applicant submits a paragraph IV certification, § 314.52 requires notice to each owner of the patent and to the holder of the approved NDA for each product claimed by the patent. The notice must go by registered or certified mail with return receipt requested, or by a designated delivery service.

What a biologics license application contains

To obtain a biologics license under section 351 of the Public Health Service Act, the manufacturer submits an application to the Director of the Center for Biologics Evaluation and Research or the Director of the Center for Drug Evaluation and Research, on the prescribed forms. Section 601.2(a) requires the application to include the following.3

  • Data from nonclinical laboratory and clinical studies demonstrating that the manufactured product meets the prescribed requirements of safety, purity and potency.
  • For each nonclinical laboratory study, a statement of compliance with part 58 or a brief statement of the reason for noncompliance.
  • Statements that each clinical investigation complied with part 56 institutional review, or was exempt under § 56.104 or § 56.105, and complied with part 50 informed consent.
  • A full description of manufacturing methods and data establishing stability through the dating period.
  • Samples representative of the product and summaries of results of tests performed on the lots represented.
  • Specimens of the labels, enclosures and containers, and any Medication Guide required under part 208.
  • The address of each location involved in the manufacture of the biological product.
  • A financial certification or disclosure statement for clinical investigators under part 54.
  • A claim for categorical exclusion under § 25.30 or § 25.31, or an environmental assessment under § 25.40.

An application for a biologics license is not considered filed until all pertinent information and data have been received by FDA.3 Under § 601.14, electronic submissions must be in a form FDA can process, review and archive, and the content of labeling required under § 201.100(d)(3) must be submitted electronically. Approval follows examination of the product and a determination of compliance with the standards in the application and with the good manufacturing practice requirements in parts 210, 211, 600, 606 and 820. A license is issued only after inspection of the establishments listed in the application, and one license covers all listed locations.3

Filing and the review clock

Within 60 days after FDA receives an NDA, the agency determines whether the application may be filed. Filing means that FDA has made a threshold determination that the application is sufficiently complete to permit substantive review. The date of filing is the date 60 days after receipt, and it begins the 180-day filing clock under section 505(c). If FDA refuses to file, the applicant may request an informal conference in writing within 30 days.

Section 314.100 gives FDA 180 days from receipt of an application or abbreviated application to send either an approval letter or a complete response letter. That period is the initial review cycle. It may be adjusted by mutual agreement or as the result of a major amendment. Submission of a major amendment to an original NDA within 3 months of the end of the initial review cycle constitutes agreement to a 3-month extension. FDA may instead defer review of the amendment to the subsequent cycle. Throughout review, § 314.102 requires FDA to communicate with applicants on scientific, medical and procedural issues, and reviewers make reasonable efforts to flag easily correctable deficiencies early.

Approval, complete response and refusal

FDA approves an NDA and sends an approval letter if none of the grounds for refusal in § 314.125 applies. A tentative approval letter issues where an application otherwise meets the requirements but cannot be approved because of exclusivity for the listed drug. A drug product granted tentative approval is not an approved drug. Reports of adequate and well-controlled investigations, with the characteristics set out in § 314.126(b), provide the primary basis for determining whether there is substantial evidence of effectiveness.

A complete response letter under § 314.110 describes all specific deficiencies the agency has identified and reflects its complete review of the data submitted. Where the data are inadequate to support approval, FDA may issue the letter without first conducting required inspections or reviewing proposed labeling. The parallel provision for biological products is § 601.3. After a complete response letter, a biologics applicant must either resubmit the application addressing all deficiencies, or withdraw it. Failure to do either within 1 year may be treated as a request to withdraw, and the applicant then has 30 days from FDA’s notification to explain why it should not be withdrawn.3 A biologics license is issued on a determination that the establishments and the product meet the applicable requirements, and remains valid until suspended or revoked.3

Changes after approval

An NDA holder must notify FDA of each change in a condition established in the approved application beyond the variations already provided for. Depending on the type of change, notification is by supplement under § 314.70(b) or (c) or by inclusion in the annual report. The holder must assess the effects of the change before distributing a product made with a manufacturing change.

For licensed biological products, § 601.12 requires the applicant to inform FDA of each change in the following.

  • the product
  • the production process
  • quality controls
  • equipment
  • facilities
  • responsible personnel
  • labeling

Major changes require a supplement approved before distribution, and the supplement contains a detailed description of the change, the products and sites affected, the methods and studies used to evaluate it, the resulting data, relevant validation protocols and a reference list of relevant standard operating procedures. Every supplement or annual report must list all changes it contains, and for supplements that list goes in the cover letter.3

Questions people also ask

When does an IND take effect?

An IND goes into effect 30 days after FDA receives it, unless FDA notifies the sponsor that the investigations described in it are subject to a clinical hold. It may take effect earlier if FDA notifies the sponsor that the clinical investigations may begin. FDA notifies the sponsor in writing of the date it received the IND.1

How many copies of a new drug application are required?

Three copies are required: an archival copy, a review copy and a field copy. The same three-copy requirement applies to an abbreviated new drug application under § 314.94.2

Does a biological product go through the NDA process?

A biological product subject to licensing under section 351 of the Public Health Service Act is the subject of a biologics license application filed under § 601.2. The application goes to the Director of the Center for Biologics Evaluation and Research or the Director of the Center for Drug Evaluation and Research on the prescribed forms.3 Part 314 states that it does not apply to drug products subject to licensing under the Public Health Service Act.

What pediatric information must a marketing application contain?

Each application for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must contain data adequate to assess safety and effectiveness in all relevant pediatric subpopulations. FDA may defer submission of some or all assessments, and may grant a full or partial waiver on request or on its own initiative. These requirements for drugs are set out in § 314.55, and § 601.27 carries the corresponding requirement for biological products.3 The corresponding provision for drugs is § 314.55.

What happens after a complete response letter?

For a biologics license application or supplement, the applicant must either resubmit the application addressing all identified deficiencies, or withdraw it. Withdrawal is without prejudice to a later submission. Where possible, the complete response letter recommends actions that would place the application in condition for approval.3

Footnotes

  1. 21 CFR Part 312, Investigational New Drug Application. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  2. 21 CFR 314.50, Content and format of an NDA. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314.50 ↩ ↩2 ↩3

  3. 21 CFR Part 601, Licensing. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-601 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9

Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.